Roy Whitfield Biography and Net Worth

Director of Nektar Therapeutics

Roy A. Whitfield has served as our director since August 2000. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation, a company he co-founded in 1991. From January 1993 to November 2001, Mr. Whitfield served as its Chief Executive Officer and from November 2001 until June 2003 as its Chairman. Mr. Whitfield still serves on the Board of Incyte Corporation. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Prior to his work at Technicon, Mr. Whitfield spent seven years with the Boston Consulting Group's international consulting practice. Mr. Whitfield received a B.S. in mathematics from Oxford University and an M.B.A. from Stanford University.

What is Roy A. Whitfield's net worth?: The estimated net worth of Roy A. Whitfield is at least $831.66 thousand as of June 14th, 2023. Mr. Whitfield owns 14,416 shares of Nektar Therapeutics stock worth more than $831,659 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Whitfield may own. Learn More about Roy A. Whitfield's net worth.
How do I contact Roy A. Whitfield?: The corporate mailing address for Mr. Whitfield and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Roy A. Whitfield's contact information.
Has Roy A. Whitfield been buying or selling shares of Nektar Therapeutics?: Roy A. Whitfield has not been actively trading shares of Nektar Therapeutics within the last three months. Most recently, Roy A. Whitfield sold 2,000 shares of the business's stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $8.55, for a transaction totalling $17,100.00. Following the completion of the sale, the director now directly owns 14,416 shares of the company's stock, valued at $123,256.80. Learn More on Roy A. Whitfield's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Roy Whitfield (Director), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 43,135 shares worth more than $1,344,931.62. The most recent insider tranaction occured on November, 25th when insider Jonathan Zalevsky sold 1,157 shares worth more than $62,801.96. Insiders at Nektar Therapeutics own 3.7% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 11/25/2025.

Roy A. Whitfield Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/14/2023	Sell	2,000	$8.55	$17,100.00	14,416
8/10/2017	Buy	2,333	$269.25	$628,160.25	8,866

Roy A. Whitfield Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $57.69

$54.75

$57.86

50 Day Range

MA: $58.84

$53.95

$65.69

2 Week Range

Now: $57.69

$6.45

$66.92

Volume

475,955 shs

Average Volume

649,746 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27